Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3029528 | 1.00 | LPAR3 (0.42) | LPAR3LPAR2LPAR1FAAHTRPV1 | |
| SCHEMBL2889638 | 0.90 | FAAH (0.52) | LPAR3LPAR2LPAR1FAAHTRPV1 | |
| SCHEMBL3035571 | 0.86 | LPAR2 (0.53) | LPAR3LPAR2LPAR1FAAHTRPV1 | |
| SCHEMBL3031132 | 0.86 | LPAR2 (0.53) | LPAR3LPAR2LPAR1FAAHTRPV1 | |
| SCHEMBL3035566 | 0.85 | LPAR3 (0.44) | LPAR3LPAR2LPAR1FAAHTRPV1 | |
| SCHEMBL3035329 | 0.85 | LPAR3 (0.44) | LPAR3LPAR2LPAR1FAAHTRPV1 | |
| SCHEMBL7483913 | 0.85 | ALDH1A1 (0.32) | LPAR3 | |
| SCHEMBL7483917 | 0.85 | ALDH1A1 (0.32) | LPAR3 | |
| SCHEMBL3024625 | 0.83 | FAAH (0.48) | LPAR3FAAHTRPV1 | |
| SCHEMBL3042596 | 0.83 | FAAH (0.48) | LPAR3FAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | MATSUDA, AKIRA (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2045256-A1 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | NUDT1, DPYD, SLC29A1 | LPAR3 2306/4885LPAR2 2934/4885LPAR1 2368/4885 |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | NUDT1, DPYD, SLC29A1 | LPAR3 2306/4885LPAR2 2934/4885LPAR1 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.